Advanced search
Publication Cover
Journal of Medical Economics Volume 12, 2009 - Issue 3
Submit an article Journal homepage
525
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer

Fabian T. Camacho Department of Health Evaluation Sciences, Pennsylvania State University College of Medicine, Hershey, PA, USA
,
Jun Wu Department of Pharmacy Practice and Administration, The Ohio State University College of Pharmacy, Columbus, OH, USA
,
Wenhui Wei Formerly at: Roche Pharmaceuticals, Nutley, NJ, USA; current address: Schering-Plough Pharmaceuticals, Kenilworth, NJ, USA
,
Gretchen Kimmick Department of Clinical Oncology, Duke University Medical Center, Durham, NC, USA
,
Roger T. Anderson Department of Health Evaluation Sciences, Pennsylvania State University College of Medicine, Hershey, PA, USA
&
Rajesh Balkrishnan University of Michigan Schools of Pharmacy and Public Health, Ann Arbor, MI, USACorrespondence[email protected]
Pages 238-245 | Accepted 18 Aug 2009, Published online: 07 Sep 2009

References

  • American Cancer Society. Cancer Facts & Figures. 2007. Available at: www.cancer.org.
  • Perez EA. Current management of metastatic breast cancer. Semin Oncol 1999;26:1-10.
  • Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005;27:23-44.
  • Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86:1367-1372.
  • Wist EA, Sommer HH, Ostenstad B, et al. Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 2004;43:186-189.
  • Gradishar WJ, Meza LA, Amin B, et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. J Clin Oncol 2004;22:2321-2327.
  • Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al. Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003;14:1227-1233.
  • O’Shaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12:1247-1254.
  • Stockler M, Sourijina T, Grimision P, et al. A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(June Suppl): (16S), Part I of II, 1031.
  • Minea L, Stanculeanu DL, Cringeanu A, et al. Capecitabine monotherapy for elderly patients with metastatic breast cancer. J Clin Oncol 2004;22:76s.
  • Bajetta E, Procopio G, Gelio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005;23:2155-2166.
  • Gradishar WJ, Meza LA, Amin B, et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. J Clin Oncol 2004;22:2321-2327.
  • Kattan J, Ghosn M, Farhat F, et al. Phase II study of vinorelbine (Navelline) and capecitabine (C) combination (Navcap) as first line treatment of metastatic breast cancer (MBC). Ann Oncol 2002;13(Suppl 5):56.
  • Malfair TS, Barnett J, Chia S. Population based cost-effectiveness analysis of combination capecitabine and docstaxel (DC) versus single agent docetaxel (D) in the treatment of metastatic breast cancer (MBC) following an anthracycline regimen. Eur J Cancer 2002;38(Suppl 3):S67.
  • Verma S, Maraninchi D, O’Shaughnessy J, et al. Capecitabine plus docetaxel combination therapy. Cancer 2005;103:2455-2465.
  • Verma S, Ilersich AL. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer. Oncologist 2003;8:232-240.
  • Hornberger JC, Jamieson C, O’Shaughnessy J. Economic evaluation of capecitabine-docetaxel combination study. Value Health 2002;5:129.
  • Baran RW, Dupere W, Susan M, et al. Clinical and economic outcomes associated with metastatic breast cancer in managed care populations: capecitabine (Xeloda) versus comparison therapies. ASCO Annual Meeting Proceedings, J Clin Oncol 2002, abstr 1942.
  • Silberman G, Gupta S, Berkowitz N, et al. Cost-effectiveness of capecitabine, continuous infusion 5-FU, gemcitabine and vinorebine in the treatment of metastatic breast cancer. ASCO Annual Meeting Proceedings. J Clin Oncol 1999, abstr 1629.
  • Anderson RT, Camacho FT, Balkrishnan R, et al. Use of cancer registry data for research on patterns of breast cancer care of individuals with Medicaid Insurance. ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(June Suppl): (16S), Part I of II, 6021.
  • D’Hoore W, Bouckaert A, Tilquin Ch. Practical considerations on the use of the Charlson comorbidity with administrative data bases. J. Clin Epidemiol 1996;49:1429-1433.
  • Diehr P, Yanez D, Ash A, Hornbrook, Lin DY. Methods for analyzing health care utilization and costs. Annu Rev Public Health 1999;20:125-144.
  • Radice D, Redaelli A. Breast cancer management: quality-of-life and cost considerations. Pharmacoeconomics 2003;21:383-396.
  • Barron JJ, Quimbo R, Nikam PT, et al. Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat 2008;109:367-377.
  • Chau I, Legge S, Fumoleau P. The vital role of education and information in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 2004;8(Suppl 1):S41-53

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.